Pneumococcal Community-Acquired Pneumonia (CAP) in Adults: Epidemiology, Pathophysiology, and Updated Vaccination Guidance
Authors:
- Christopher W. BlackwellCBChristopher W. Blackwell
- Humberto López CastilloHCHumberto López Castillo
- Frances ArmstrongFAFrances Armstrong
- 29 October 2025
- journal article
- Published by Elsevier in The Journal for Nurse Practitioners
- Vol. 21 (10)
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Post-licensure Safety Surveillance of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among US Adults in the Vaccine Adverse Event Reporting System (VAERS)Drug Safety, 2024
- Streptococcus pneumoniae epidemiology, pathogenesis and controlNature Reviews Microbiology, 2024
- Community-Acquired PneumoniaJAMA, 2024
- Risk of Pneumococcal Disease in US Adults by Age and Risk ProfileOpen Forum Infectious Diseases, 2023
- Vaccine hesitancy educational tools for healthcare providers and trainees: A scoping reviewVaccine, 2022
- Pneumococcal vaccination for adultsThe Nurse Practitioner, 2022
- Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 YearsClinical Infectious Diseases, 2021
- A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of ageVaccine, 2021
- A critical gap: Advanced practice nurses focused on the public's healthNursing Outlook, 2021
- Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeClinical Infectious Diseases, 2020